Erudio Healtherudio.com
Clinical trial · no report yet · Phase not applicable
START-MET trial: what clinicians have said so far
START-MET HS Prostate Cancer. : SbrT & Androgen Receptor Therapy METastatic HSPC
- NCT05209243 ↗
- Recruiting
- Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on START-MET (castration sensitive oligometastatic prostate cancer; tests a strategy, not a drug) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on START-MET so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 5 posts on X, typically up to 22 once built |
The trial
ClinicalTrials.gov- Official title
- Phase III Study of Stereotactic Body Radiation Therapy (SBRT) Plus Standard of Care in Castration Sensitive Oligometastatic Prostate Cancer Patients.
- Phase
- Phase not applicable
- Status
- Recruiting
- Conditions
- Prostate Cancer; Stereotactic Body Radiation Therapy
- Interventions
- SBRT; STANDARD OF CARE
- Arms
- Interventional arm · Experimental
- Control arm · Active comparator
- Enrollment
- 266 (estimated)
- Primary outcomes
- Radiological progression-free survival (rPFS)
- Sponsor
- Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
- Start
- Jan 26, 2023
- Primary completion
- Jan 2025 (estimated)
- Results posted
- No
- Registry record
- NCT05209243 · updated May 19, 2023